Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Sonidegib (Odomzo) is used for treating adult patients with locally advanced basal cell carcinoma (BCC) that has recurred after surgery or radiation therapy, or for those who are not candidates for surgery or radiation therapy.
• Two studies were analyzed to gather information about this medication.
• These studies compared sonidegib with vismodegib, both are sonic hedgehog inhibitors used in treating BCC and metastatic BCC, as well as medulloblastoma. Safety profiles showed common adverse effects such as muscle spasms, dysgeusia, alopecia, but sonidegib users reported more nausea and diarrhea, whereas vismodegib users experienced more weight loss.
• In treating BCC, the overall response rate was 50.1% for sonidegib versus 68.5% for vismodegib; despite the difference, both medications are considered effective, but high discontinuation rates suggest the importance of managing expectations.
• For SHH-driven medulloblastoma treatment, sonidegib had a significantly higher overall response rate than vismodegib, particularly among pediatric patients where its efficacy was found to be 3.67 times higher than that of vismodegib's.
• Efficacy and safety evaluations for both adults with BCC and children/adults with SHH-driven medulloblastoma highlighted sonidegib's increased efficacy in pediatric patients, suggesting it could be a preferred option for treating this subgroup due to its targeted therapeutic potential against their specific cancer type.